DK2680873T3 - Svampedræbende midler og anvendelser deraf - Google Patents

Svampedræbende midler og anvendelser deraf Download PDF

Info

Publication number
DK2680873T3
DK2680873T3 DK12751994.0T DK12751994T DK2680873T3 DK 2680873 T3 DK2680873 T3 DK 2680873T3 DK 12751994 T DK12751994 T DK 12751994T DK 2680873 T3 DK2680873 T3 DK 2680873T3
Authority
DK
Denmark
Prior art keywords
compound
pharmaceutical composition
compounds
integer
mmol
Prior art date
Application number
DK12751994.0T
Other languages
English (en)
Inventor
Kenneth Duke James Jr
Christopher Patrick Laudeman
Navdeep Balkrishna Malkar
Balasingham Radhakrishnan
Original Assignee
Cidara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics Inc filed Critical Cidara Therapeutics Inc
Application granted granted Critical
Publication of DK2680873T3 publication Critical patent/DK2680873T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (15)

1. Forbindelse med formlen:
eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse ifølge krav 1, hvor forbindelsen er et acetatsalt eller et kloridsalt.
3. Farmaceutisk sammensætning omfattende forbindelsen ifølge krav 1, eller et farmaceutisk acceptabelt salt deraf, og en farmaceutisk acceptabel excipiens.
4. Farmaceutisk sammensætning ifølge krav 3 omfattende acetatsaltet eller kloridsaltet af en forbindelse ifølge krav 1.
5. Farmaceutisk sammensætning ifølge krav 3 eller 4, hvor den farmaceutiske sammensætning er formuleret til topikal, parenteral, intravenøs, intra-arteriel, subkutan, intramuskulær, intrakranial, intraorbital, ophthalmisk, intraventrikulær, intrakapsulær, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, via suppositorier eller oral indgivelse.
6. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 3-5 til anvendelse til behandling afen svampeinfektion hos et individ.
7. Farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor den farmaceutiske sammensætning er formuleret til oral indgivelse.
8. Farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor den farmaceutiske sammensætning er formuleret til intravenøs indgivelse.
9. Farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor den farmaceutiske sammensætning er formuleret til topikal indgivelse.
10. Farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor den farmaceutiske sammensætning er formuleret til subkutan indgivelse.
11. Farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor den farmaceutiske sammensætning er formuleret til inhalering.
12. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 6-11, hvor den farmaceutiske sammensætning indgives til behandling af en blodstrømsinfektion eller vævsinfektion hos individet.
13. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 6-12, hvor svampeinfektionen er valgt fra tinea capitis, tinea corporis, tinea pedis, onychomykose, perionychomykose, pityriasis versicolor, svamp i mundhulen, vaginal candidosis, candidosis i luftvejene, galdestenscandidosis, candidosis i spiserøret, candidosis i urinvejene, systemisk candidosis, mucokutan candidosis, aspergillose, mucormykose, paracoccidioidomykose, nordamerikansk blastomykose, histoplasmose, coccidioidomykose, sporotrichose, mykotisk sinuit eller kronisk sinuit.
14. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 6-13, hvor svampeinfektionen er en infektion af Candida albicans, C. parapsilosis, C. giabrata, C. guilliermondii, C. krusei, C. tropicalis, C. lusitaniae, Aspergillus fumigatus, A. flavus, A. terreus, A. niger, A. candidus, A. clavatus eller A. ochraceus.
15. Forbindelse ifølge krav 1, eller et farmaceutisk acceptabelt salt deraf, til anvendelse til at forebygge, stabilisere eller inhibere væksten af svampe, eller at dræbe svampe.
DK12751994.0T 2011-03-03 2012-03-02 Svampedræbende midler og anvendelser deraf DK2680873T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448807P 2011-03-03 2011-03-03
PCT/US2012/027451 WO2012119065A2 (en) 2011-03-03 2012-03-02 Antifungal agents and uses thereof

Publications (1)

Publication Number Publication Date
DK2680873T3 true DK2680873T3 (da) 2017-10-30

Family

ID=46758514

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12751994.0T DK2680873T3 (da) 2011-03-03 2012-03-02 Svampedræbende midler og anvendelser deraf

Country Status (18)

Country Link
US (5) US8722619B2 (da)
EP (2) EP2680873B1 (da)
JP (4) JP5809296B2 (da)
CN (2) CN103889221B (da)
CA (2) CA2865791C (da)
CY (1) CY1119709T1 (da)
DK (1) DK2680873T3 (da)
ES (1) ES2645074T3 (da)
FI (1) FIC20240022I1 (da)
HR (1) HRP20171579T8 (da)
HU (1) HUE036778T2 (da)
LT (1) LT2680873T (da)
NO (1) NO2680873T3 (da)
PL (1) PL2680873T3 (da)
PT (1) PT2680873T (da)
RS (1) RS56426B1 (da)
SI (1) SI2680873T1 (da)
WO (1) WO2012119065A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012119065A2 (en) 2011-03-03 2012-09-07 Seachaid Pharmaceuticals, Inc. Antifungal agents and uses thereof
HRP20231151T1 (hr) * 2012-03-19 2024-01-05 Cidara Therapeutics, Inc. Režimi za doziranje spojeva iz klase ehinokandina
WO2015035102A2 (en) * 2013-09-04 2015-03-12 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
US20170042162A1 (en) * 2014-04-28 2017-02-16 University Of Central Florida Research Foundation, Inc. Compositions, methods of making a composition, and methods of use
WO2016201283A1 (en) * 2015-06-12 2016-12-15 Cidara Therapeutics, Inc. Antifungal agents
US20180256673A1 (en) * 2015-09-16 2018-09-13 Cidara Therapeutics, Inc. Methods for treating fungal infections
CN106674333B (zh) * 2015-11-06 2020-10-27 博瑞生物医药（苏州）股份有限公司 一种环肽类抗真菌化合物及其制备方法
WO2017120471A1 (en) 2016-01-08 2017-07-13 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
WO2017161016A1 (en) * 2016-03-16 2017-09-21 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
US20210002346A1 (en) * 2016-11-29 2021-01-07 Cidara Therapeutics, Inc Methods for preventing fungal infections
EP3577129A1 (en) * 2017-01-31 2019-12-11 Cidara Therapeutics, Inc. Methods for treating fungal infections
WO2019014333A1 (en) * 2017-07-12 2019-01-17 Cidara Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS
CN112839951A (zh) * 2018-06-15 2021-05-25 奇达拉治疗公司 棘白菌素类抗真菌剂的合成
WO2020086931A1 (en) * 2018-10-25 2020-04-30 Cidara Therapeutics, Inc. Polymorph of echinocandin antifungal agent
CN114616238A (zh) 2019-12-06 2022-06-10 上海森辉医药有限公司 棘白菌素类似物及其制备方法
WO2022253297A1 (zh) 2021-06-03 2022-12-08 上海森辉医药有限公司 一种阿尼芬净衍生物的制备方法
CN116903706B (zh) * 2023-06-13 2024-05-17 深圳市祥根生物有限公司 一种棘白菌素类药物及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030944A (en) * 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5399552A (en) 1991-10-17 1995-03-21 Merck & Co, Inc Antibiotic peptides bearing aminoalkylthioether moieties
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
US5948753A (en) 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
AU674233B2 (en) * 1993-05-04 1996-12-12 Merck & Co., Inc. Cyclohexapeptidyl aminoalkyl ethers
AU7874494A (en) * 1993-09-22 1995-04-10 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5541160A (en) * 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5514651A (en) 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
EP0805685B1 (en) 1995-01-26 2001-09-26 Merck & Co., Inc. Novel antifungal cyclohexapeptides
US5652213A (en) * 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
DK1137663T3 (da) * 1998-12-09 2007-01-08 Lilly Co Eli Oprensning af Echinocandin-cyclopeptidforbindelser
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN1345230A (zh) 1999-03-03 2002-04-17 伊莱利利公司 口服ecb药物制剂和药物组合物的制备方法
US6610822B2 (en) 2000-09-01 2003-08-26 Merck & Co., Inc. Purification process
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
ATE381957T1 (de) * 2003-07-22 2008-01-15 Theravance Inc Verwendung eines antimykotischen echinocandin- mittels in kombination mit einem antibakteriellen glycopeptid-mittel
US20070231258A1 (en) * 2006-03-31 2007-10-04 Karyon Ctt Ltd. Peptide conjugates
US20090238867A1 (en) 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
CN102421790A (zh) * 2009-05-07 2012-04-18 帝斯曼知识产权资产管理有限公司 制备环肽的方法
EP2470190A4 (en) 2009-08-27 2013-07-17 Seachaid Pharmaceuticals Inc ECHINOCANDINDERIVATE
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
WO2012119065A2 (en) 2011-03-03 2012-09-07 Seachaid Pharmaceuticals, Inc. Antifungal agents and uses thereof

Also Published As

Publication number Publication date
WO2012119065A2 (en) 2012-09-07
EP2680873B1 (en) 2017-08-09
ES2645074T3 (es) 2017-12-04
CY1119709T1 (el) 2018-06-27
RS56426B1 (sr) 2018-01-31
JP2017132770A (ja) 2017-08-03
FIC20240022I1 (fi) 2024-06-19
US9217014B2 (en) 2015-12-22
JP2016029052A (ja) 2016-03-03
US20150024997A1 (en) 2015-01-22
EP3192803B1 (en) 2020-12-09
NO2680873T3 (da) 2018-01-06
PL2680873T3 (pl) 2018-01-31
CN103889221B (zh) 2016-08-31
SI2680873T1 (sl) 2017-12-29
US20170253635A1 (en) 2017-09-07
CA3053850A1 (en) 2012-09-07
ES2645074T8 (es) 2018-09-28
JP2018118977A (ja) 2018-08-02
US20130244930A1 (en) 2013-09-19
CN103889221A (zh) 2014-06-25
EP3192803A1 (en) 2017-07-19
HRP20171579T8 (hr) 2018-12-14
JP2014516339A (ja) 2014-07-10
JP6111447B2 (ja) 2017-04-12
US20220162263A1 (en) 2022-05-26
HUE036778T2 (hu) 2018-07-30
JP6302108B2 (ja) 2018-03-28
CA2865791A1 (en) 2012-09-07
EP2680873A2 (en) 2014-01-08
WO2012119065A3 (en) 2014-03-13
JP5809296B2 (ja) 2015-11-10
US8722619B2 (en) 2014-05-13
CN106279369A (zh) 2017-01-04
EP2680873A4 (en) 2015-08-26
CA2865791C (en) 2019-10-08
HRP20171579T1 (hr) 2018-02-09
LT2680873T (lt) 2017-11-27
CN106279369B (zh) 2020-02-11
PT2680873T (pt) 2017-11-01
US9676821B2 (en) 2017-06-13
US20160075740A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
DK2680873T3 (da) Svampedræbende midler og anvendelser deraf
CA2747995A1 (en) Antibiotic compositions for the treatment of gram negative infections
US20120190613A1 (en) Echinocandin derivatives
WO2016201283A1 (en) Antifungal agents
WO2018187574A1 (en) Compositions and methods for the treatment of fungal infections
Fujie Discovery of micafungin (FK463): A novel antifungal drug derived from a natural product lead
FUJIE et al. FR901469, a Novel Antifimgal Antibiotic from an Unidentified Fungus No. 11243 II. In Vitro and In Vivo Activities
Fujie et al. FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties
Bossche Echinocandins-an update
EP0539088B1 (en) Echinocandin b derivative
AU2022340625A1 (en) Peptides with antimicrobial activities
CN117897394A (zh) 具有抗微生物活性的胜肽
CN113710248A (zh) 抗真菌剂
Balkovec et al. The fungal cell wall as a drug discovery target: Sar of novel echinocandin analogs
Mulder Design, Synthesis and Evaluation of Macrocyclic Antifungal Peptides